Yunhua Deng

Wuhan, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Exosomal miR-493-3p Promote the Secretion of CXCL10 by Suppressing Keratinocyte Autophagy in Vitiligo.

Exosomal miR-493-3p Promote the Secretion of CXCL10 by Suppressing Keratinocyte Autophagy in Vitiligo.

Journal: Clinical, cosmetic and investigational dermatology
Published: September 11, 2025

Cold atmospheric plasma (CAP) stimulates melanoblast-to-melanocyte differentiation via PRKCQ upregulation and NF-κB activation.

Cold atmospheric plasma (CAP) stimulates melanoblast-to-melanocyte differentiation via PRKCQ upregulation and NF-κB activation.

Journal: iScience
Published: August 22, 2025

A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52).

A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52).

Journal: Journal of the American Academy of Dermatology
Published: April 24, 2025

A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis.

A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis.

Journal: Journal of the American Academy of Dermatology
Published: October 07, 2024

Case report: Clinicopathological characteristics of SASH1 mutation-related dyschromatosis: a rethinking of the classification of dyschromatosis.

Case report: Clinicopathological characteristics of SASH1 mutation-related dyschromatosis: a rethinking of the classification of dyschromatosis.

Journal: Frontiers in genetics
Published: April 08, 2024

The role of dermal fibroblasts in autoimmune skin diseases.

The role of dermal fibroblasts in autoimmune skin diseases.

Journal: Frontiers in immunology
Published: January 31, 2024

Clinical features and biomarker differences of severe intrinsic and extrinsic atopic dermatitis.

Clinical features and biomarker differences of severe intrinsic and extrinsic atopic dermatitis.

Journal: Cutaneous and ocular toxicology
Published: January 23, 2024

CCL19 promotes TNF-alpha/IFN-gamma-induced production of cytokines by targeting CCR7/NF-κB signalling in HaCaT cells.

CCL19 promotes TNF-alpha/IFN-gamma-induced production of cytokines by targeting CCR7/NF-κB signalling in HaCaT cells.

Journal: Folia histochemica et cytobiologica
Published: January 01, 2024

Exosomal miRNAs in autoimmune skin diseases.

Exosomal miRNAs in autoimmune skin diseases.

Journal: Frontiers in immunology
Published: October 04, 2023

1,25-Dihydroxyvitamin D3 Provides Benefits in Vitiligo Based on Modulation of CD8+ T Cell Glycolysis and Function.

1,25-Dihydroxyvitamin D3 Provides Benefits in Vitiligo Based on Modulation of CD8+ T Cell Glycolysis and Function.

Journal: Nutrients
Published: September 26, 2023

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.

Journal: Chinese medical journal
Published: June 24, 2023

Idiopathic Hypereosinophilia in an Elderly Male with Contraindications to Glucocorticoids and Good Response to Omalizumab.

Idiopathic Hypereosinophilia in an Elderly Male with Contraindications to Glucocorticoids and Good Response to Omalizumab.

Journal: Indian journal of dermatology
Published: March 31, 2023
Showing 1-12 of 25

Last Updated: 09/26/2026